Niox Group PLC
LSE:NIOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Niox Group PLC
Change in Working Capital
Niox Group PLC
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Niox Group PLC
LSE:NIOX
|
Change in Working Capital
-£700k
|
CAGR 3-Years
60%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Change in Working Capital
-$75.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Change in Working Capital
-£9.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Change in Working Capital
-$14.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-83%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Change in Working Capital
-£52.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-9%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Change in Working Capital
£8.4m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Niox Group PLC
Glance View
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.
See Also
What is Niox Group PLC's Change in Working Capital?
Change in Working Capital
-700k
GBP
Based on the financial report for Dec 31, 2025, Niox Group PLC's Change in Working Capital amounts to -700k GBP.
What is Niox Group PLC's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
45%
The average annual Change in Working Capital growth rates for Niox Group PLC have been 60% over the past three years , 45% over the past five years .
